Evidence That Hyperglycemia After Recovery From Hypoglycemia Worsens Endothelial Function and Increases Oxidative Stress and Inflammation in Healthy Control Subjects and Subjects With Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Currently there is debate on whether hypoglycemia is an independent risk factor for atherosclerosis, but little attention has been paid to the effects of recovery from hypoglycemia. In normal control individuals and in people with type 1 diabetes, recovery from a 2-h induced hypoglycemia was obtained by reaching normoglycemia or hyperglycemia for another 2 h and then maintaining normal glycemia for the following 6 h. Hyperglycemia after hypoglycemia was also repeated with the concomitant infusion of vitamin C. Recovery with normoglycemia is accompanied by a significant improvement in endothelial dysfunction, oxidative stress, and inflammation, which are affected by hypoglycemia; however, a period of hyperglycemia after hypoglycemia worsens all of these parameters, an effect that persists even after the additional 6 h of normoglycemia. This effect is partially counterbalanced when hyperglycemia after hypoglycemia is accompanied by the simultaneous infusion of vitamin C, suggesting that when hyperglycemia follows hypoglycemia, an ischemia–reperfusion-like effect is produced. This study shows that the way in which recovery from hypoglycemia takes place in people with type 1 diabetes could play an important role in favoring the appearance of endothelial dysfunction, oxidative stress, and inflammation, widely recognized cardiovascular risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, these agents promote hemodynamic equilibrium,18 diminish thrombotic propensity,448 alleviate endothelial oxidative stress,449 attenuate inflammatory processes,450 and foster a favorable balance of the gut microbiota,451 all of which collectively contribute to the salutary effects of these agents in patients with AS.”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [449]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 2×
“(ACCORD) trial (18) and possibly in the Veterans Affairs Diabetes Trial (VADT) (19) and Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) (20) studies has caused concern, because intensive treatment had tripled the frequency of severe hypoglycemia.”
BackgroundCorretti, M. C., Anderson, T. J., Benjamin, E. J., Celermajer, D., Charbonneau, F., Creager, M. A., Deanfield, J., Drexler, H., Gerhard-Herman, M., Herrington, D., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01746-6 · Cited by 4,604
Severe hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471
The Value of Cardiovascular Autonomic Function Tests: 10 Years Experience in Diabetes
Ewing, D. J., Martyn, C. N., Young, R. J., & Clarke, B. F. (1985) · Diabetes Care · doi:10.2337/diacare.8.5.491 · Cited by 1,434
Gold, A. E., Macleod, K. M., & Frier, B. M. (1994) · Diabetes Care · doi:10.2337/diacare.17.7.697 · Cited by 810
Suh, S. W., Gum, E. T., Hamby, A. M., Chan, P. H., & Swanson, R. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30077 · Cited by 419 · cited 3×
“There is, however, evidence that free radical production rises, not only during hypoglycemia but particularly during glucose reperfusion after hypoglycemia (9).”
BackgroundResultDetection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress
Mercuri, F., Tonutti, L., Taboga, C., Ceriello, A., Assaloni, R., Motz, E., & Quagliaro, L. (2001) · Diabetologia · doi:10.1007/s001250100529 · Cited by 419
Self-citationCeriello, A., Ihnat, M. A., & Thorpe, J. E. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1824 · Cited by 413
Self-citationVascular disease and diabetes: Is hypoglycaemia an aggravating factor?
Wright, R. J., & Frier, B. M. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.865 · Cited by 336 · cited 3×
“Recent evidence suggests that hypoglycemia may play an important role in the vascular complications of diabetes (1).”
BackgroundAmiel, S. A., Tamborlane, W. V., Simonson, D. C., & Sherwin, R. S. (1987) · New England Journal of Medicine · doi:10.1056/nejm198705283162205 · Cited by 309
Gogitidze Joy, N., Hedrington, M. S., Briscoe, V. J., Tate, D. B., Ertl, A. C., & Davis, S. N. (2010) · Diabetes Care · doi:10.2337/dc09-0354 · Cited by 239
Antecedent Hypoglycemia Impairs Autonomic Cardiovascular Function
Adler, G. K., Bonyhay, I., Failing, H., Waring, E., Dotson, S., & Freeman, R. (2009) · Diabetes · doi:10.2337/db08-1153 · Cited by 216 · cited 1×
“This concept is not new at all to hypoglycemia; for example, baroreflex sensitivity and sympathetic response to hypotension are attenuated after previous hypoglycemia (24).”
BackgroundProinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects
Razavi Nematollahi, L., Kitabchi, A. E., Stentz, F. B., Wan, J. Y., Larijani, B. A., Tehrani, M. M., Gozashti, M. H., Omidfar, K., & Taheri, E. (2009) · Metabolism · doi:10.1016/j.metabol.2008.10.018 · Cited by 210 · cited 1×
“Consistent with this hypothesis is the evidence that hyperglycemia (6) and hypoglycemia both produce endothelial dysfunction and inflammation through the generation of oxidative stress (4,7).”
BackgroundJohnston, S. S., Conner, C., Aagren, M., Smith, D. M., Bouchard, J., & Brett, J. (2011) · Diabetes Care · doi:10.2337/dc10-1915 · Cited by 189
Singh, P. K., Jain, A., & Kaur, G. (2004) · Molecular and Cellular Biochemistry · doi:10.1023/b:mcbi.0000026067.08356.13 · Cited by 163
Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality
Wei, M., Gibbons, L. W., Mitchell, T. L., Kampert, J. B., Stern, M. P., & Blair, S. N. (2000) · Circulation · doi:10.1161/01.cir.101.17.2047 · Cited by 142 · cited 1×
“Two epidemiologic studies have determined that hypoglycemia results in an increased risk of cardiovascular disease and all-cause mortality (16,17), whereas the increase in cardiovascular mortality in people with type 2 diabetes in the Action to Control Cardiovascular Risk in Diabetes TABLE 1 Baseline characteristics o…”
BackgroundWang, J., Alexanian, A., Ying, R., Kizhakekuttu, T. J., Dharmashankar, K., Vasquez-Vivar, J., Gutterman, D. D., & Widlansky, M. E. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.227389 · Cited by 136
Dewald, O., Sharma, S., Adrogue, J., Salazar, R., Duerr, G. D., Crapo, J. D., Entman, M. L., & Taegtmeyer, H. (2005) · Circulation · doi:10.1161/circulationaha.105.536318 · Cited by 106
Imaging myocardial metabolism and ischemic memory
Taegtmeyer, H., & Dilsizian, V. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1186 · Cited by 68
Clinical Implications of the ACCORD Trial
Genuth, S., & Ismail-Beigi, F. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1679 · Cited by 56
Ceriello, A. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000368193.24732.66 · Cited by 51
Self-citationNandish, S., Wyatt, J., Bailon, O., Smith, M., OLIVEROS, R. A., & CHILTON, R. J. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.015 · Cited by 32
Mullan, B. A., Ennis, C. N., Fee, H. J. P., Young, I. S., & McCance, D. R. (2005) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2005.04193.x · Cited by 24
Cited by
Reactive Oxygen Species in Inflammation and Tissue Injury
Mittal, M., Siddiqui, M. R., Tran, K., Reddy, S. P., & Malik, A. B. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.5149 · Cited by 4,897
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
Glycaemic variability in diabetes: clinical and therapeutic implications
Ceriello, A., Monnier, L., & Owens, D. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30136-0 · Cited by 588
Self-citationPapachristoforou, E., Lambadiari, V., Maratou, E., & Makrilakis, K. (2020) · Journal of Diabetes Research · doi:10.1155/2020/7489795 · Cited by 479
Metadata
- Authors
- Ceriello, A., Novials, A., Ortega, E., La Sala, L., Pujadas, G., Testa, R., Bonfigli, A. R., Esposito, K., & Giugliano, D.
- Affiliations
- Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (ES)
- Department of Endocrinology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Hospital Clínic de Barcelona (ES)
- Istituto Nazionale di Riposo e Cura per Anziani (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Corresponding author
- Ceriello, Antonio
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2012-10-16
- Volume
- 61
- Issue
- 11
- Pages
- 2993-2997
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3478543
- OpenAlex
- W2107614741
- Cited by
- 155
- References
- 25
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 6 · 2023: 11 · 2022: 9 · 2021: 16 · 2020: 17 · 2019: 14 · 2018: 12 · 2017: 10 · 2016: 14 · 2015: 12 · 2014: 14 · 2013: 9 · 2012: 2
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- hypoglycemia, hyperglycemia, endothelial dysfunction, oxidative stress, inflammation, type 1 diabetes, vitamin C, ischemia-reperfusion, atherosclerosis risk, cardiovascular risk factors
- MeSH terms
- Adult, Antioxidants, Ascorbic Acid, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Endothelium, Vascular, Female, Glucose, Humans, Hyperglycemia, Hypoglycemia, Hypoglycemic Agents, Infusions, Intravenous, Insulin, Male, Risk Factors, Vasodilation, Oxidative Stress, Cross-Over Studies, Inflammation Mediators, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.